Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

194.92 +0.71 (+0.37%)
Streaming Delayed Price Updated: 1:04 PM EDT, Sep 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
60 61 Next >
Our Predictions for the Top 7 Dividend Stocks for 2023
Dividend stocks will be an ideal way for investors to practice patient in 2023. Here are my dividend stock predictions for 2023. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
These companies are safe havens during tough times, with above-average dividends. 
Via The Motley Fool
$1000 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
Via Benzinga
If You Invested $25,000 in AbbVie In 2020, This Is How Much You Would Have Today
In May 2020, the company closed on its acquisition of Botox maker Allergan. 
Via The Motley Fool
Check Out What Whales Are Doing With ABBV
A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 17 strange trades. 
Via Benzinga
2 Forever Stocks You Can Buy and Forget About
These stocks are both beating the market this year. 
Via The Motley Fool
A Bullish Sign Appears On AbbVie's Chart
Via Benzinga
$1000 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Here's Why the Bear Market Could End in 2023
Now could be the opportune time to load up on some quality growth stocks. 
Via The Motley Fool
This Unstoppable Growth Stock Is Nearing a Once-In-a-Decade Buying Opportunity
The risk of a stalled top line in 2023 means the potential for reward for those who can see beyond it. 
Via The Motley Fool
2 Mammoth Stocks With Dividends to Buy Before 2022 Ends
Blue chip healthcare stocks Johnson & Johnson and Cigna are always in season. 
Via The Motley Fool
Top 15 Investing Tips for Beginners in 2023 and Beyond
These investing tips for beginners will help you be a better long-term investor. 
Via The Motley Fool
2 Exceptional Dividend Growth Stocks to Buy Now
These companies have histories of rapid payout increases and the means to continue them. 
Via The Motley Fool
Tuesday Talk: Where is Santa?
Monday continued the downtrend for the major indices on Wall Street which concluded a second week of losses on Friday. As for an annual Santa rally, that seems nowhere to be found. 
Via Talk Markets
Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro
The biotech sector has not done well in 2022 despite some strong runs. Small and mid-cap stocks are more “risk-off’ with interest rates rising and sentiment waning. 
Via Talk Markets
AbbVie's Antipsychotic Drug Scores FDA Approval As Adjunct Therapy For Depression Patients
Via Benzinga
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
Biotech is one of the safest, recession-proof sectors on the market. It's why we're going after the hottest biotech stocks in the New Year. 
Via InvestorPlace
6 Stocks Warren Buffett Completely Exited in 2022
Despite being an active buyer this year, Buffett's company Berkshire Hathaway also sold several of its holdings as it repositioned its portfolio. 
Via The Motley Fool
3 Supercharged Dividend Stocks to Buy If There's a Stock Market Sell-Off
Dividends are an investor's best friend in any market environment. 
Via The Motley Fool
Why Pfizer Stock Is Riskier Than AbbVie
Pfizer has a lot more revenue at risk over the next several years than AbbVie does. 
Via The Motley Fool
2 Dividend Stocks That Could Double Your Return in 10 Years
Both companies should hurdle their patent cliff concerns. 
Via The Motley Fool
Looking Into AbbVie's Recent Short Interest
AbbVie's (NYSE:ABBV) short percent of float has risen 5.48% since its last report. The company recently reported that it has 13.66 million shares sold short, which is 0.77% of all regular shares that... 
Via Benzinga
Finding 20 Dividend Growth Stocks In A Bad Market
Starting in 2012, it became more and more difficult for prudent dividend growth stock investors looking for income. The stock market was trading at excessive valuations, and interest rates were at... 
Via Talk Markets
The 7 Best Investment Funds to Navigate a Possible Recession
With a possible recession on the horizon, investors may be able to protect themselves through the best investment funds. 
Via InvestorPlace
2 Stocks to Buy With Dividends Yielding More Than 3%
Nearly a forgotten art, dividend growth investing is back -- and for a compelling reason. 
Via The Motley Fool
Reliable Passive Income: an Analysis on Dividend Kings
A Dividend King is any stock that has increased its dividend for 50+ cosecutive years, doubling that of a Dividend Aristocrat. 
Via The Motley Fool
2 Ultra-Reliable Dividend Stocks You Can Buy Now and Hold Forever
Here are two stocks that investors can count on to deliver increasing dividend payments for many years to come. 
Via The Motley Fool
Have $1,000? 2 Top Dividend Stocks to Buy Right Now
Dividend stocks can help investors grow their portfolios in all types of markets. 
Via The Motley Fool
3 Hot Stocks That Could Live Up to Their Lofty Valuations
These companies have long runways of growth ahead 
Via The Motley Fool
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
60 61 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.